iBio, Inc. (IBIO:NYSEMKT) closed at $0.766 on October 16, 2026, down 2.11% on the day. The stock trades 79.9% below its 52-week high of $3.82 and 5.0% above its 52-week low of $0.730. Over the past year, it lost 9.8%. iBio, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -15.16% | -38.70% | -44.07% | -61.10% | -9.85% |
In 252 trading sessions since October 16, 2025, IBIO closed higher on 102 days (40%). Its best day was December 8, 2025 (+39.17%) and its worst was March 26, 2026 (-20.18%). The stock moved 10% or more in a single session 23 times. It opened at least 5% above the previous day's high 8 times.
iBio, Inc., a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The company's proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; iBioModulator, a technology platform that is designed to enhance the potency and duration of effect of prophylactic and therapeutic vaccines; and iBio Advanced Technologies. Its therapeutic protein product candidates comprise IBIO-CFB03 for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody. The company's vaccine candidates include H1N1 Influenza and H5N1 Influenza viral disease vaccines, which have completed Phase I clinical trials; Yellow Fever viral disease vaccine, which is in preclinical stage; Human Papillomavirus therapeutic vaccine; and malaria and hookworm parasitic pathogen vaccines, which are in Phase I clinical trials. Its biodefense product candidates includ...
Find more stocks like IBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.